Physician profile
Noel Totti
NPI 1649237181
$10,621.48
in general payments reported to CMS, 2019-2025
25 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $1,115 · 2021: $1,423 · 2022: $1,567 · 2023: $1,257 · 2024: $1,872 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,393 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,393.43 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,129.94 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,116.73 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,661.11 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $895.72 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $536.99 | 2019-2025 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $286.16 | 2021-2025 | Glassia, Hyqvia |
| Amgen INC. | $252.40 | 2021-2025 | Tezspire |
| United Therapeutics Corporation | $242.33 | 2024-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $226.39 | 2022-2025 | Winrevair, Capvaxive |
| Mylan Specialty L.P. | $203.16 | 2022-2024 | Yupelri |
| Pbg Puerto Rico LLC | $156.93 | 2019-2021 | |
| Genentech USA, INC. | $151.37 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $136.75 | 2019-2022 | |
| Insmed, INC. | $131.76 | 2023-2024 | Arikayce |
| Eli Lilly Export S.A. Puerto Rico Branch | $122.00 | 2025 | Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan LLC | $109.38 | 2020-2021 | |
| Viatris Specialty LLC | $49.90 | 2025 | Yupelri |
| Pfizer INC. | $49.80 | 2023 | |
| Genentech, INC. | $40.18 | 2021 | |
| Liquidia Technologies, INC. | $23.33 | 2025 | Yutrepia |
| Gilead Sciences, INC. | $22.30 | 2021 | |
| Edwards Lifesciences Corporation | $20.90 | 2019 | |
| Pfizer Pharmaceuticals LLC | $20.00 | 2019 | |
| Sanofi US Services INC. | $20.00 | 2024 | |
| Shire North American Group INC | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Totti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.